Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT

Erin Gomez; Phuoc T. Tran; Kenneth J. Pienta; Martin G. Pomper; Michael A. Gorin; Steven P. Rowe

doi:10.1097/RLU.0000000000002489

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted ¹⁸F-DCFPyL PET/CT

Erin Gomez, Phuoc T. Tran, Kenneth J. Pienta, Martin G. Pomper, Michael A. Gorin, Steven P. Rowe

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted ¹⁸F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of ¹⁸F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.

Original language	English
Pages (from-to)	e313-e314
Journal	Clinical Nuclear Medicine
Volume	44
Issue number	4
DOIs	https://doi.org/10.1097/RLU.0000000000002489
State	Published - 1 Apr 2019
Externally published	Yes

Keywords

F-DCFPyL
PSMA-RADS
PSMA-targeted PET
hereditary spherocytosis
prostate cancer

Access to Document

10.1097/RLU.0000000000002489

Cite this

@article{aabf819a21e64863bf71cda29127f5bb,

title = "Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT",

abstract = "We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted 18F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of 18F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.",

keywords = "F-DCFPyL, PSMA-RADS, PSMA-targeted PET, hereditary spherocytosis, prostate cancer",

author = "Erin Gomez and Tran, {Phuoc T.} and Pienta, {Kenneth J.} and Pomper, {Martin G.} and Gorin, {Michael A.} and Rowe, {Steven P.}",

year = "2019",

month = apr,

day = "1",

doi = "10.1097/RLU.0000000000002489",

language = "English",

volume = "44",

pages = "e313--e314",

journal = "Clinical Nuclear Medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "4",

}

TY - JOUR

T1 - Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT

AU - Gomez, Erin

AU - Tran, Phuoc T.

AU - Pienta, Kenneth J.

AU - Pomper, Martin G.

AU - Gorin, Michael A.

AU - Rowe, Steven P.

PY - 2019/4/1

Y1 - 2019/4/1

N2 - We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted 18F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of 18F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.

AB - We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy. PSMA-targeted 18F-DCFPyL PET/CT was performed, which demonstrated recurrent disease in the prostatectomy bed as well as splenomegaly and mild-diffuse bone marrow activation, consistent with the patient's history of hereditary spherocytosis. We briefly review the clinical characteristics of hereditary spherocytosis, its appearance on molecular imaging studies, the normal biodistribution of 18F-DCFPyL, and the PSMA-RADS scoring system for characterizing findings on PSMA-targeted PET imaging.

KW - F-DCFPyL

KW - PSMA-RADS

KW - PSMA-targeted PET

KW - hereditary spherocytosis

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85062402187&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002489

DO - 10.1097/RLU.0000000000002489

M3 - Article

C2 - 30789396

AN - SCOPUS:85062402187

SN - 0363-9762

VL - 44

SP - e313-e314

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

IS - 4